An Analysys Of Stock-for-stock M&A By Listed Companies

With the rapid development of the stock market of our country China, listing Corporation completed the listing after the transaction, to expand the scope of business through a number of financial operation mode, to enhance corporate value and competitiveness, so that its share price rise, will bring more opportunities for business and revenue. The M&A has been used by more and more enterprises. Especially in the past two years, the market emerged in a number of successful mergers and acquisitions in the transaction process exposed some problems worth thinking about. Based on the background, development and Prospect of China’s listing Corporation mergers and acquisitions, based on the theory of M&A research and analysis, to explore the influence of the pharmaceutical industry mergers and acquisitions in the external market factors, the will of M&A, internal financial status, the decision-making factors of shareholders. At the same time make a deep research and analysis on the evaluation of enterprises on the pharmaceutical sector. The paper has theoretical discussions and empirical evidence of the case--Shanghai RAAS to issue A shares and private placement of equity to total 1800000000 yuan to acquisition of state and pharmaceutical 100% stake, a detailed analysis was carried out from the point of view, the use of income method and market method to evaluate the enterprise value.